BillionToOne, Inc.(BLLN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #747 of 2,962 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BLLN Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for BillionToOne, Inc. (BLLN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BLLN at 61.9/100 on a 32-signal composite quality model, placing it at rank #747 of 2,962 stocks — the top half of the AI-ranked universe. BLLN scores in the top quartile across institutional flow (98.1), revenue growth (93.2). Areas of concern include revenue scale (33.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BillionToOne, Inc. reports quarterly revenue of $109.4M, net income of $8.1M, an operating margin of 5.0%. Top institutional holders of BLLN by reported 13-F value include ADAMS STREET PARTNERS, PRICE T ROWE ASSOCIATES, BAILLIE GIFFORD, based on the most recent SEC filings. BLLN trades on the Nasdaq exchange and files with the SEC under CIK 2070849. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BillionToOne, Inc. directly from SEC EDGAR. BillionToOne, Inc.'s 13F Pro composite quality score has ranged between 47 and 63 since 2026, currently 61.9 — a stable long-term trajectory across 19 quarterly and live scoring snapshots.
Revenue
Q2 2026
$109.4M
Net Income
Q2 2026
$8.1M
Free Cash Flow
Q2 2026
$5.1M
Operating Margin
Q2 2026
5.0%
ROIC
Q2 2026
3.5%
D/E Ratio
Q2 2026
0.17
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+100.0% YoYNet Income
+117.9% YoYOperating Income
+134.0% YoYEPS (Diluted)
+103.4% YoYTotal Assets
+109.4% YoYTotal Debt
+11.2% YoYOp. Cash Flow
+159.4% YoYFree Cash Flow
+133.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $305.1M +100.0% | $152.6M +112.7% | $71.7M | — |
| Net Income | $7.5M +117.9% | $-41.6M +49.7% | $-82.7M | — |
| Operating Income | $16.0M +134.0% | $-47.1M +32.2% | $-69.5M | — |
| EPS (Diluted) | $0.14 +103.4% | $-4.12 +51.2% | $-8.45 | — |
| Total Assets | $632.7M +109.4% | $302.1M | — | — |
| Total Debt | $57.2M +11.2% | $51.5M | — | — |
| Operating Cash Flow | $24.6M +159.4% | $-41.4M +22.9% | $-53.7M | — |
| Free Cash Flow | $15.7M +133.6% | $-46.8M +21.8% | $-59.8M | — |
Get alerted when BLLN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BillionToOne, Inc. including:
Top Institutional Holders of BLLN
ADAMS STREET PARTNERS LLC
$205.3M1,711,430 shPRICE T ROWE ASSOCIATES INC /MD/
$121.2M1,010,322 shBAILLIE GIFFORD & CO
$108.2M901,420 shVANGUARD PORTFOLIO MANAGEMENT LLC
$100.9M840,970 shInvesco Ltd.
$100.3M835,614 shVANGUARD CAPITAL MANAGEMENT LLC
$95.9M799,468 shNeuberger Berman Group LLC
$91.7M764,215 shBAMCO INC /NY/
$89.0M742,093 shWASATCH ADVISORS LP
$62.2M518,084 shMILLENNIUM MANAGEMENT LLC
$51.0M425,032 sh
| Fund | Value | Shares |
|---|---|---|
| ADAMS STREET PARTNERS LLC | $205.3M | 1,711,430 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $121.2M | 1,010,322 |
| BAILLIE GIFFORD & CO | $108.2M | 901,420 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $100.9M | 840,970 |
| Invesco Ltd. | $100.3M | 835,614 |
| VANGUARD CAPITAL MANAGEMENT LLC | $95.9M | 799,468 |
| Neuberger Berman Group LLC | $91.7M | 764,215 |
| BAMCO INC /NY/ | $89.0M | 742,093 |
| WASATCH ADVISORS LP | $62.2M | 518,084 |
| MILLENNIUM MANAGEMENT LLC | $51.0M | 425,032 |
Companies Similar to BLLN
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Omada Health, Inc.
Adaptive Biotechnologies Corp
CORCEPT THERAPEUTICS INC
ANI PHARMACEUTICALS INC
INSULET CORP
Eton Pharmaceuticals, Inc.
AtriCure, Inc.
Progyny, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put BLLN on your watchlist
Track score changes the day BillionToOne, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BLLN a good stock to buy?
13F Pro's AI-powered analysis of BillionToOne, Inc. (BLLN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BLLN are available on the BLLN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BLLN is classified as a mid company.
Which hedge funds own BLLN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BLLN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BillionToOne, Inc.'s investment landscape.